Table 3.
Proteins identified to be significantly different for post-transplant CKD as compared to the healthy control group.
| Target | Post-transplant CKD patients relative to healthy | Biological pathways | |
|---|---|---|---|
| Transplant/healthy | p value | ||
| Cystatin C | 1.9 | < 0.0001 | Protein degradation |
| IGFBP-6 | 1.9 | 0.0002 | Cell proliferation, angiogenesis |
| REG4 | 1.8 | < 0.0001 | Cell proliferation, generation |
| CD59 | 1.6 | < 0.0001 | Complement-induced lysis, T cell activation |
| Ephrin-A4 | 1.6 | 0.0002 | Angiogenesis |
| EFNB2 | 1.6 | 0.0001 | Angiogenesis |
| SMOC1 | 1.5 | < 0.0001 | Angiogenesis, fibrosis |
| Ephrin-A2 | 1.5 | < 0.0001 | Angiogenesis |
| VEGF-D | 1.5 | < 0.0001 | Angiogenesis |
| Endostatin | 1.5 | < 0.0001 | Angiogenesis |
| TIMP-1 | 1.4 | < 0.0001 | Extracellular matrix |
| NEGR-1 | 1.3 | < 0.0001 | Cell adhesion, axonal sprouting |
The data are shown ratiometrically for relative fluorescence units (RFU) for CKD/healthy control. CKD: chronic kidney disease, IGFBP-6: insulin-like growth factor-binding protein, VEGF: vascular endothelial growth factor, SECTM1: secreted and transmembrane protein 1, REG4: regenerating islet-derived protein 4, Ephrin: Eph family receptor interacting proteins, EFN: ephrin. p value was considered significant < 0.0002 for individuals proteins, TIMP-1: tissue inhibitor of metalloproteinases, NEGR: neuronal growth regulator.